Szegedi A, Kohnen R, Dienel A, Kieser M
Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy, Eschenallee 3, 14050 Berlin, Germany.
BMJ. 2005 Mar 5;330(7490):503. doi: 10.1136/bmj.38356.655266.82. Epub 2005 Feb 11.
To investigate the efficacy of hypericum extract WS 5570 (St John's wort) compared with paroxetine in patients with moderate to severe major depression.
Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial.
21 psychiatric primary care practices in Germany.
251 adult outpatients with acute major depression with total score > or = 22 on the 17 item Hamilton depression scale.
900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders doses were increased to 1800 mg/day hypericum or 40 mg/day paroxetine after two weeks.
Change in score on Hamilton depression scale from baseline to day 42 (primary outcome). Secondary measures were change in scores on Montgomery-Asberg depression rating scale, clinical global impressions, and Beck depression inventory.
The Hamilton depression total score decreased by mean 14.4 (SD 8.8) points, corresponding to 56.6% (SD 34.3%) of the baseline value, in the hypericum group and by 11.4 (SD 8.6) points (44.8% (SD 33.5%) of baseline value) in the paroxetine group (intention to treat analysis; similar results were observed in the per protocol analysis). The intention to treat analysis (lower one sided 97.5% confidence limit 1.5 points for the difference hypericum minus paroxetine) and the per protocol analysis (lower confidence limit 0.7 points) showed non-inferiority of hypericum and statistical superiority over paroxetine. The lower limits in both cases exceeded the pre-specified non-inferiority margin of -2.5 points and the superiority margin of 0. The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine, respectively.
In the treatment of moderate to severe major depression, hypericum extract WS 5570 is at least as effective as paroxetine and is better tolerated.
研究金丝桃提取物 WS 5570(圣约翰草)与帕罗西汀相比治疗中度至重度重度抑郁症患者的疗效。
随机双盲、双模拟、对照参照、多中心非劣效性试验。
德国 21 家精神科初级保健机构。
251 名成人门诊急性重度抑郁症患者,17 项汉密尔顿抑郁量表总分≥22 分。
金丝桃提取物 WS 5570 900 毫克/天,每日 3 次,或帕罗西汀 20 毫克/天,每日 1 次,持续 6 周。初始无反应者在 2 周后剂量增加至金丝桃提取物 1800 毫克/天或帕罗西汀 40 毫克/天。
从基线到第 42 天汉密尔顿抑郁量表评分的变化(主要指标)。次要指标为蒙哥马利-阿斯伯格抑郁评定量表、临床总体印象和贝克抑郁量表评分的变化。
金丝桃提取物组汉密尔顿抑郁量表总分平均下降 14.4(标准差 8.8)分,相当于基线值的 56.6%(标准差 34.3%),帕罗西汀组下降 11.4(标准差 8.6)分(基线值的 44.8%(标准差 33.5%))(意向性分析;符合方案分析结果相似)。意向性分析(金丝桃提取物减去帕罗西汀差异的单侧 97.5%置信下限为 1.5 分)和符合方案分析(置信下限为 0.7 分)显示金丝桃提取物非劣于帕罗西汀且在统计学上优于帕罗西汀。两种情况下的下限均超过预先设定的非劣效界值 -2.5 分和优效界值 0。金丝桃提取物和帕罗西汀的不良事件发生率分别为每暴露日 0.035 次和 0.060 次。
在治疗中度至重度重度抑郁症方面,金丝桃提取物 WS 5570 至少与帕罗西汀一样有效,且耐受性更好。